Phase II study of high-dose ifosfamide in hepatocellular carcinoma

Abstract

A phase II study of high-dose ifosfamide in hepatocellular carcinoma was conducted among 17 Chinese patients. The dose of ifosfamide used was 2.5 g/m2 daily given as a continuous infusion for 5 days. In all, 15 patients were evaluable for tumour response. There was no complete or partial responder. The treatment was well tolerated. The most frequent toxicity was alopecia, which occurred in 11 patients, and 5 patients developed mild haematological toxicity. There was no evidence of liver or bladder toxicity. Overall, 14 patients were evaluable for survival. The median survival was 92 days (range, 30–568 days). We conclude that high-dose ifosfamide is well tolerated but ineffective in hepatocellular carcinoma in Chinese patients.

DOI: 10.1007/BF00685682

3 Figures and Tables

Statistics

0200400'00'02'04'06'08'10'12'14'16
Citations per Year

358 Citations

Semantic Scholar estimates that this publication has 358 citations based on the available data.

See our FAQ for additional information.

Cite this paper

@article{Lin1993PhaseIS, title={Phase II study of high-dose ifosfamide in hepatocellular carcinoma}, author={J. C. Lin and Wesely C. T. Shiu and Wai-tong Leung and M. Tao and N. W. Leung and Wan Yee Joseph Lau and Arthur K. C. Li}, journal={Cancer Chemotherapy and Pharmacology}, year={1993}, volume={31}, pages={338-339} }